Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: January 18, 2008
Last updated: March 15, 2012
Last verified: February 2011
This study is designed to assess the safety and tolerability of single, escalating oral doses and repeat oral doses (7 days, once daily) of GSK835726 in healthy male subjects

Condition Intervention Phase
Allergic Rhinitis
Rhinitis, Allergic, Seasonal
Drug: GSK835726
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
Official Title: See Detailed Description

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • ECG monitoring during 24 hours after each dose in the single dose cohorts and on days 1 and 7 in the repeat dose cohorts. [ Time Frame: during 24 hours after each dose in the single dose cohorts and on days 1 and 7 in the repeat dose cohorts. ]
  • Heart rate and blood pressure changes over 24 hours after dosing in single and repeat dose cohorts [ Time Frame: over 24 hours after dosing in single and repeat dose cohorts ]

Secondary Outcome Measures:
  • Change in plasma drug concentration (AUC, Cmax, t1/2, tmax) [ Time Frame: over 24 hours after dosing. ]
  • Changes in histamine-induced wheal and flare measurements [ Time Frame: over 24 hours after dosing. ]
  • Derived pharmacokinetic parameters for GSK835726 including area under the plasma drug concentration versus time curve (AUC(0-t), AUC(0-¥)), maximum observed plasma drug concentration (Cmax),
  • time to maximum observed plasma drug concentration (tmax), apparent clearance (CL/F) and terminal half life (t1/2) following single and repeat oral dosing.

Estimated Enrollment: 40
Study Start Date: October 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Detailed Description:
A double-blind, placebo controlled, randomized cross-over single dose escalation study and a double-blind, placebo controlled, randomised parallel group 7-days once daily repeat dose study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of oral H1/H3 dual antagonist compound in healthy male subjects

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Male aged between 18 and 50 years inclusive.
  • Body mass index within the range 19-29kg/m2 (inclusive), with weight range of 55kg-100kg (inclusive).
  • Healthy (defined as individuals who are free from significant nasal, cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, malignancy, endocrine, neurological and psychiatric disease as determined by history, physical examination and screening investigations).
  • Non-smoking status as verified by urinary cotinine levels below 300 ng/mL cotinine at the screening visit. This can include ex-smokers who have given up smoking for >1 year.
  • Subjects to be entered in cohorts I and III only: Skin prick test reactivity to histamine of 3mm wheal > than saline control and some associated surrounding erythema.
  • Subjects to be entered in cohorts I and III only: Negative skin prick test reactivity to saline control.
  • The subject is able and willing to give written informed consent to take part in the study and is available to complete all study measurements.
  • If sexually active, male subjects must agree to use a condom with spermicide during sexual intercourse, from the first dose of the study drug until 84 days after the last dose. In addition, female partners of male subjects, who are of childbearing potential, must use a reliable contraceptive method or they must refrain from sexual intercourse from the first dose of study medication until 84 days after the last dose. Reliable forms of contraception include an IUD, condom or diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants, contraceptive patches or a tubal ligation."

Exclusion criteria:

  • As a result of the medical interview, physical examination or screening investigations, the Investigator or appropriately qualified designee considers the subject unfit for the study.
  • The subject has a history of drug or any other allergy, which, in the opinion of the Investigator or appropriately qualified designee, contraindicates their participation, including known or suspected personal history or family history of adverse reactions or hypersensitivity to anti histamines.
  • The subject has participated in a study with a new molecular entity during the previous 3 months or any other study during the previous 2 months.
  • The subject regularly, or on average, drinks more than 21 units of alcohol a week or more than an average intake of 3 units per day (One unit = 125ml wine or 25ml spirits or 250ml normal strength lager).
  • The subject is currently taking regular (or a course of) medication, prescribed (including all anti-allergy medication) or not (including over the counter medication or herbal remedies such as St Johns Wort). Paracetamol is an exception and will be permitted at daily doses of up to 4g following all doses of investigational product.
  • The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.
  • The subject has tested positive for HIV.
  • The subject has a positive drugs of abuse and alcohol test.
  • Donation of blood (450 mL or more) within 2 months of screening.
  • Donation during the study would result in >500mL of blood being donated over a 56 day period
  • Significant cardiac conduction abnormalities on two or more ECG tracings separated by at least 5 minutes at screening, including:

    • QTc interval > 450 msec
    • PR interval > 240 msec
    • Evidence of second- or third- degree atrioventricular (AV) block
    • Ventricular rate < 45 beats per minute (bpm) or > 100 bpm
    • Pathological Q-waves (defined as Q-wave > 40 msec or depth greater than 0.4-0.5 mV)
    • Evidence of ventricular pre-excitation
    • Evidence of left axis deviation, non-specific intraventricular conduction delay (QRS duration > 120 msec), or complete left bundle branch block
  • Subjects with Perennial Allergic Rhinitis (PAR) and Seasonal Allergic Rhinitis (SAR), unless subjects with SAR are asymptomatic and it is outside of the pollen season
  • Subjects with dermatographism and other skin conditions that might interfere with the wheal and flare test.
  • Subjects who are unable to comply with study procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00605852

United Kingdom
GSK Investigational Site
London, United Kingdom, NW10 7EW
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00605852     History of Changes
Other Study ID Numbers: HH3110161 
Study First Received: January 18, 2008
Last Updated: March 15, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by GlaxoSmithKline:
Allergic rhinitis,
first time in human

Additional relevant MeSH terms:
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Nose Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Otorhinolaryngologic Diseases
Hypersensitivity, Immediate
Immune System Diseases
Respiratory Tract Infections processed this record on October 25, 2016